摘要
目的观察重组人p53腺病毒注射液联合顺铂治疗肺癌所致心包积液的临床疗效。方法将84例诊断为肺癌晚期所致心包积液的患者分为观察组和对照组,各42例,患者在采用一次性中心静脉导管行心包积液引流后,对照组给予顺铂注射液40mg/m2心包内注射,每周重复1次,连续使用4周;观察组给予重组人p53腺病毒注射液1×1012 VP联合顺铂注射液40mg/m2心包内注射,每周重复1次,连续使用4周。比较治疗后二组患者治疗心包积液疗效、生活质量改善情况及不良反应等。结果观察组有效率高于对照组,患者生活质量改善情况明显优于对照组,差异具统计学意义(P<0.05)。观察组除发热例数多于对照组(P<0.05),其余不良反应二组差异无统计学意义(P>0.05)。结论重组人p53腺病毒注射液联合顺铂治疗肺癌心包积液疗效确定,有效改善患者生活质量,安全可靠,是一种有效的治疗手段,值得临床推广应用。
Objective To observe the effect of P53 recombinant human Adenovirus combined with Cisplatin in the treatment of pericardial effusion caused by lung cancer. Methods Eightyfour cases of patients diagnosed with advanced lung cancer due to pericardial effusion were randomly divided into the observation group and the control group, 42 cases of patients after onetime central venous catheter drainage of pericardial effusion. The control group received Cisplatin injection liquid 40mg/m2 intrapericardial injection, repeated once a week, four weeks of continuous; while the observation group received recombinant Adenovirus p53 injection combined with Cisplatin 1 × 10^12 VP injection 40mg/m2 intrapericardial injection, repeated once a week, continuous use 4 weeks. Some indexes were compared between the two groups of patients after treatment such as pericardial effusion, improvement of quality of life and adverse reactions. Results The observation group was higher efficiency, quality of life improvement than the control group, the difference was statistically significant （P〈0.05）. Number of fever cases in the observation group than the control group（P〈0.05）, there was no significant difference （rest of adverse reactions：P 〉0.05）. Conclusion The recombinant p53 Adenovirus combined with Cisplatin in the treatment of lung cancer to determine pericardial effusion, improve patient quality of life, safety and reliability, is an effective treatment, worthy of clinical application.
出处
《中国煤炭工业医学杂志》
2016年第10期1407-1410,共4页
Chinese Journal of Coal Industry Medicine
基金
2015年度河北省医学科学研究重点课题计划(编号:20150981)
关键词
重组人P53腺病毒
顺铂
心包积液
Recombinant human adenovirus P53
Cisplatin
Pericardial effusion
